B.Sc. (Dunelm), M.Sc., Ph.D., C.Stat., RSS Fellow
Telephone: 01223 (7) 61762
Mark is a Senior Research Associate in the Cambridge Research Methods Hub (CRMH) & the Behaviour and Health Research Unit (BHRU). He has a background within both academia (medical consultancy at Sheffield University & health-care research at Manchester University) and also the Pharmaceutical industry (statistical genetics, safety assessment & drug discovery for AstraZeneca, and clinical studies for GSK/Novartis).
He has reviewed ~70 papers, a number of NIHR grants was a grant award panel member for the national NC3Rs body (2017-9), currently acts as expert reviewer for Health Research Council of New Zealand and Heath & Care Wales on national grants, sat for two years on the RSS Medical Statistics committee (2017-8) and has acted/acts as an independent Statistician on TSC of a number of successful trials. The majority of his ~60 publications relate to a variety of different types of healthcare studies.
– B.Sc. Mathematics, Durham, 1991
– M.Sc. Statistics, Sheffield, 1995
– Ph.D. Statistics & Ecology, Sheffield, 2001
Over the past few years, his work has involved supporting multiple projects at the BHRU covering such statistical techniques as meta-analysis, Bayesian meta-regression, generalized linear models, zero-inflated repeated-measures regression, hurdle models, GEE, GAMLSS, machine learning approaches, hierarchical models. Previous projects have included Rasch analysis, assessing agreement, questionnaire development, survey data analysis, biomarker discovery, statistical genetics, statistical process control, adaptive trial design, SW-CRCT design…
These tools support his interest in the field of Healthcare Statistics, and more specifically Trial Design; especially sample size estimation.
Guest lecturer on 2018 & 2019 M.Sc. Biostatistics course. Taught on 2019 Clinical Trials module of M.Sc. Biostatistics course. Module leader (Surveys) on the 2020 M.Sc. Public Health/Epidemiology course
Lecturer on M.Res. i) Statistics, ii) Design courses, Manchester University 2011-2016
The effect of wine glass size on volume of wine sold: A mega-analysis of studies in bars and restaurants. M Pilling, N Clarke, R Pechey, GJ Hollands, TM Marteau. 2020. Addiction.
Cigarette pack size and consumption: a parallel group adaptive randomised controlled trial. I Lee, A Blackwell, M Scollo, K De-Loyde, R Morris, M Pilling, M Wakefield, MR Munafò, TM Marteau. 2020. (In review).
Impact of increasing the proportion of healthier foods available on energy purchased in worksite cafeterias: A stepped wedge randomized controlled pilot trial. R Pechey, E Cartwright, M Pilling, GJ Hollands, M Vasiljevic, SA Jebb, TM Marteau. 2019. Appetite 133, 286-296.
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. A Nardone, H Weir, O Delpuech, H Brown, C De Angelis, ML Cataldo, X Fu, MJ Shea, T Mitchell, J Veeraraghavan, C Nagi, M Pilling, MF Rimawi, M Trivedi, SG Hilsenbeck, GC Chamness, R Jeselsohn, CK Osborne, R Schiff. 2019. British Journal of Cancer 120 (3), 331.
A multi-center preclinical study of Gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function. A Karageorgis, S Lenhard, B Yerby, M Forsgren, S Liachenko, E Johansson, M Pilling, R Peterson, X Yang, D Williams, S Ungersma, R Morgan, K Brouwer, B Jucker, P Hockings. 2018. Plos One.
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. W Proctor, A Foster, J Vogt, C Summers, B Middleton, M Pilling, D Shienson, M Kijanska, S Ströbel, J Kelm, P Morgan, S Messner, D Williams. 2017. Arch Toxicol. 91(8), 2849-2863.
Feasibility study to prevent falls in older people who are sight impaired: the VIP2UK randomised controlled trial. H Waterman, C Ballinger, C Brundle, S Chastin, H Gage, R Harper, D Henson, B Laventure, L McEvoy, M Pilling, N Olleveant, D A Skelton, P Stanford, C Todd. 2016. Trials 17(1), 464.
The theoretical and practical determination of clinical cut-offs for the British Sign Language versions of PHQ-9 and GAD-7. R Belk, M Pilling, KD Rogers, K Lovell, A Young. 2016. BMC Psychiatry 16:372.
Recommendations for managing missing data, attrition and response shift in palliative and end-of-life care research : Part of the MORECare research method guidance on statistical issues. N Preston, P Fayers, S Walters, M Pilling, G Grande, V Short, E Owen-Jones, C Evans, H Benalia, I Higginson, C Todd. 2013. Palliative Medicine 27(10) 899-907.
An Exploratory Study to Clarify the Cluster of Symptoms Predictive of Chemotherapy-Related Nausea Using Random Forest Modeling. A Molassiotis, C Farrell, K Bourne, SG Brearley, M Pilling. 2012. Journal of Pain and Symptom Management 44(5), 692-703.
Mark is a book reviewer for the RSS, and a member of Trinity Hall Cambridge.
Within Mark’s role, he regularly gives presentations on statistical topics, consult on project design and collaborates with Ph.D. students on their projects across the IPH.